This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Iovance Biotherapeutics Faces...
Business class action

Iovance Biotherapeutics Faces Securities Lawsuit

Analysis based on 16 articles · First reported May 15, 2025 · Last updated Jun 06, 2025

Sentiment
-70
Attention
4
Articles
16
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Atara Biotherapeutics for alleged securities fraud has led to a significant decline in its stock price, negatively impacting investors. This event highlights the risks associated with misleading statements from publicly traded companies and the potential for legal repercussions.

Biotechnology Legal Services
Event Summary

Atara Biotherapeutics is facing a class action securities lawsuit initiated by Levi & Korsinsky on behalf of investors who suffered losses due to alleged securities fraud between May 9, 2024, and May 8, 2025. The lawsuit claims that Atara Biotherapeutics disseminated false and misleading statements regarding its growth potential and ability to capitalize on demand for its treatments. On July 25, 2024, Atara Biotherapeutics announced its Q2 2024 financial results and reduced its full fiscal year 2024 revenue guidance, attributing it to scheduled maintenance, lower Proleukin sales, and variable patient treatment pace. Following this news, Atara Biotherapeutics's stock price dramatically declined by approximately 44.795% on May 9, 2025. Investors have until July 14, 2025, to request to be appointed as lead plaintiff in the lawsuit filed in the United States — United States District Court for the Northern District of California.

Key Actions
100 Levi & Korsinsky notifies investors of lawsuit Atara Biotherapeutics
95 Atara Biotherapeutics reported financial results
Entities Involved
stock
Atara Biotherapeutics
Atara Biotherapeutics is facing a class action lawsuit for alleged securities fraud, which led to a significant drop in its stock price.
Importance 100.0 Sentiment -80.0
priv
Levi & Korsinsky
Levi & Korsinsky is the law firm initiating the class action lawsuit against Atara Biotherapeutics on behalf of affected investors.
Importance 80.0 Sentiment 60.0
per
Joseph E. Levi
Joseph E. Levi is an attorney at Levi & Korsinsky, serving as a contact for investors interested in the class action lawsuit against Atara Biotherapeutics.
Importance 40.0 Sentiment 50.0
govactor
United States — United States District Court for the Northern District of California
Importance 0.0 Sentiment 0.0
index
Nasdaq-100
Importance 0.0 Sentiment 0.0
Relationships
Levi & Korsinsky related ↔ Joseph E. Levi
Levi & Korsinsky related ↔ United States — United States District Court for the Northern District of California
Joseph E. Levi related ↔ United States — United States District Court for the Northern District of California
United States — United States District Court for the Northern District of California related ↔ Nasdaq-100
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.